Pain relief in oral mucositis
OncoZenge is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer.
5 million people worldwide suffer from oral mucositis after cancer therapy. Oral mucositis is the most debilitating side effect of radiation therapy and chemotherapy. After radiotherapy in the head and neck region, 90% of patients develop OM and of the patients treated with chemotherapy, about 30% are affected. OM causes severe pain, interruption of cancer treatments and increased healthcare costs.
OM causes severe pain
Oral mucositis has a significant impact on the quality of life of cancer patients. It may cause severe pain, difficulties in eating and drinking as well as in swallowing and communicating. OM leads to:
- 62% of patients need to be hospitalized*
- 70% of patients need tube feeding*
- 35% of patients must reduce the dose or discontinue their cancer treatment*
In clinical studies, BupiZenge® has been shown to significantly reduce pain in the mouth and throat.
*Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M. Perspectives on cancer therapy-induced mucosal injury. Cancer. 2004;100(9 Suppl):1995-2025
ONCOZENGE AB INTERIM REPORT JANUARY – JUNE 2023
ONCOZENGE POSTPONES INTERIM REPORT FOR THE SECOND QUARTER OF 2023
THREE BOARD MEMBERS ALONG WITH THE MANAGING DIRECTOR OF ONCOZENGE HAVE TENDERED THEIR RESIGNATIONS
BULLETIN FROM ONCOZENGE´S EXTRAORDINARY GENERAL MEETING ON AUGUST 21, 2023
ONCOZENGE IS PAUSING THE DEVELOPMENT OF BUPIZENGE®
NOTICE OF EXTRAORDINARY GENERAL MEETING IN ONCOZENGE AB (Publ)
DELAY IN DEVELOPMENT WORK FOR BUPIZENGE®
BULLETIN FROM ONCOZENGE´S AGM ON MAY 31, 2023
ONCOZENGE INTERIM REPORT JAN-MAR 2023
ONCOZENGE RECEIVES RESPONSES FROM REGULATORY AUTHORITIES IN EUROPE AND THE US
ONCOZENGE ANNUAL REPORT 2022
OncoZenge is a Swedish pharmaceutical company founded in 2020 as a spin-out from Moberg Pharma in collaboration with leading clinicians from Hvidovre Hospital in Denmark.
The original invention was made in 2011 by Professor Ove Andersen and his team who developed a novel concept to provide better pain relief for patients with OM. Since then clinical studies in Phase 1 and Phase 2 have demonstrated the efficacy and safety of BupiZenge®.
Subscribe to press releases & financial reports
Add your e-mail adress to get the latest news and reports
BupiZenge® can radically improve quality of life for patients with severe oral pain, originating for example from radiation therapy or chemotherapy of cancer.More about our main project BupiZenge® here